Original article| Volume 56, ISSUE 3, P248-255, March 2003

Meaningful effect size and patterns of response of the transition dyspnea index


      Ths object of this study was to examine validity, meaningful effect sizes, and patterns of response of the Transition Dyspnea Index (TDI) in a clinical trial cohort of chronic obstructive pulmonary disease (COPD) patients. The design was a retrospective analysis of data from a randomized, double-blind placebo-controlled clinical trial. We analyzed fifty clinical investigation sites in United States. There were 921 patients with stable COPD. Tiotropium 18 μg dry powder or matching placebo was used. Patients were allowed to remain on usual care less ipratropium bromide. Construct validity was demonstrated by significant correlations (P < .05) between Baseline Dyspnea Index (BDI) and other baseline measures, as well as between TDI and changes in other measures at the end of 1 year. Concurrent validity was observed by the significant correlation between TDI and dyspnea diary responses. Changes in TDI focal score were in the range of one unit when the group was stratified by a minimal change in the physician's global evaluation. Significantly less (P < .05) supplemental albuterol was observed in the group of responders defined by a one-unit improvement in TDI. Responders also had few exacerbations and better health status. The validity of the TDI is supported in a large clinical trial setting. A one-unit change in the TDI focal score represented the minimal important difference.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Epidemiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Official Statement of the ATS
        Dyspnea. Mechanisms, assessment, and management.
        Am J Respir Crit Care Med. 1999; 159: 321-340
        • Mahler D.A
        Clin Chest Med. 1987; 8: 215-230
        • Mahler D.A
        • Guyatt G.H
        • Jones P.W
        Clinical measurement of dyspnea.
        in: Mahler D.A Dyspnea. Marcel Dekker, Inc.;, New York1998: 149-198
        • Mahler D.A
        • Weinberg D.H
        • Wells C.K
        • Feinstein A.R
        The measurement of dyspnea.
        Chest. 1984; 85: 751-758
        • Harver A
        • Mahler D.A
        • Daubenspeck J.A
        Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease.
        Ann Intern Med. 1989; 111: 117-124
        • Lisboa C
        • Munoz V
        • Beroiza T
        • Leiva A
        • Cruz E
        Inspiratory muscle training in chronic airflow limitation.
        Eur Respir J. 1994; 7: 1266-1274
        • O'Donnell D.E
        • McGuire M.A
        • Samis L
        • Webb K.A
        The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation.
        Am J Respir Crit Care Med. 1995; 152: 2005-2013
        • Reardon J
        • Awad E
        • Normandin E
        • Vale F
        • Clark B
        • ZuWallack R.L
        The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea.
        Chest. 1994; 105: 1046-1052
        • Foglio K
        • Bianchi L
        • Bruletti G
        • Battista L
        • Pagani M
        • Ambrosino N
        Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction.
        Eur Respir J. 1999; 13: 125-132
        • Ramirez-Venegas A
        • Ward J.L
        • Olmstead E.M
        • Tosteson A.N
        • Mahler D.A
        Effect of exercise training on dyspnea measures in patients with chronic obstructive pulmonary disease.
        J Cardiopulm Rehab. 1997; 17: 103-109
        • Martinez F.J
        • Montez de Oca M
        • Whyte R.I
        • Stetz J
        • Gay S.E
        • Celli B.R
        Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function.
        Am J Respir Crit Care Med. 1997; 155: 1984-1990
        • Kirsten D.K
        • Wegner R.E
        • Jorres R.A
        • Magnussen H
        Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease.
        Chest. 1993; 104: 1101-1107
        • Mahler D.A
        • Matthay R.A
        • Snyder P.E
        • Wells C.K
        • Loke J
        Sustained-release theophylline reduces dyspnea in nonreversible obstructive airway disease.
        Am Rev Respir Dis. 1985; 131: 22-25
        • Mahler D.A
        • Donohue J.F
        • Barbee R.A
        • Goldman M.D
        • Gross N.J
        • Wisniewski M.E
        • Yancey S.W
        • Zakes B.A
        • Rickard K.A
        • Anderson W.H
        Efficacy of salmeterol xinafoate in the treatment of COPD.
        Chest. 1999; 115: 957-965
        • Casaburi R
        • Mahler D.A
        • Jones P.W
        • Wanner A
        • San Pedro G
        • ZuWallack R.L
        • Menjoge S.S
        • Serby C.W
        • Witek Jr, T.J
        A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
        Eur Respir J. 2002; 19: 217-224
        • Witek T.J
        • Souhrada J.F
        • Serby C.W
        • Disse B
        Tiotropium (Ba679).
        in: Spector S.S Anticholinergic agents in the upper and lower airways. Marcel Dekker, Inc.;, New York1999: 137-152
        • American Thoracic Society
        Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD).
        Am J Respir Crit Care Med. 1995; 152: S77-S120
        • Ware J.E
        • Sherbourne C.D
        The MOS 36-item short-form health survey (SF-36).
        Med Care. 1992; 30: 472-483
        • Jones P.W
        • Quirk F.H
        • Baveystock C.M
        • Littlejohns P
        A self-complete measure for chronic airflow limitation—the St George's Respiratory Questionnaire.
        Am Rev Respir Dis. 1992; 145: 1321-1327
        • Samsa G
        • Edelman D
        • Rothman M.L
        • Williams G.R
        • Lipscomb J
        • Matchar D
        Determining clinically important differences in health status measures.
        Pharmacoeconomics. 1999; 15: 141-155
        • Redelmeier D
        • Guyatt G.H
        • Goldstein R.S
        Assessing the minimal important difference in symptoms.
        J Clin Epidemiol. 1996; 49: 1215-1219